DocumentRX-2420
Issued
Read5 min

Blackstone Puts $1.5B Into Pfizer Obesity Drug, Buys No Rights

Blackstone funds Pfizer's berobenatide to the tune of $1.5B without gaining drug rights, while J&J, Roche, Novartis, Lilly and Moderna all post major numbers in a packed pharma week.

TAG K-1191 · 1,028 words on the filing

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout - Pharmaceutical Executive
Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout - Pharmaceutical Executivejarmoluk / pixabay

Summary of findings

  • Blackstone will fund up to $1.5B of Pfizer's berobenatide development through 2028 for milestone payments only, with no drug rights.
  • Roche's Wilserdly plus everolimus cut progression or death risk by 62% (HR 0.38) in the Phase III evERA trial; adjuvant PDUFA date is November 30.
  • Lilly broke ground on a $3.5B Pennsylvania plant, operational by 2031, within a $50B U.S. manufacturing expansion.
  • Moderna raised 2026 revenue growth guidance to 15–25% after Interpath-001 showed a 42% reduction in recurrence or death risk.
  • The FDA has effectively shelved the CNPV program; 22 vouchers were issued and 12 of those drugs are approved.

Blackstone-managed funds will pay up to $1.5 billion of development costs for Pfizer's berobenatide through 2028 — and receive no ownership in the drug. The structure, announced this week, gives Blackstone milestone payments tied to U.S. approval of monthly injectable dosing and to commercial sales targets. Pfizer keeps full operational control of every development decision.

The appeal for Pfizer is accounting, not science. Berobenatide sits at Phase III with 10 ongoing or planned trials in 2026, spanning obesity, knee osteoarthritis and obstructive sleep apnea. In the Vesper-3 study it delivered up to 12.3% placebo-adjusted weight loss at 28 weeks. The drug is not approved. What the deal buys is a way to fund an expensive late-stage obesity program while keeping part of the capital exposure off Pfizer's own books.

Who else wrote checks this week?

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront plus roughly $1.125 billion in milestones. The prize is OLN324, a late-stage bispecific antibody for retinal disease. In parallel, Blackstone Life Sciences will hand J&J $750 million to fully fund OLN324's Phase III development, in exchange for milestones and single-digit royalties — a mirror of the Pfizer structure announced the same week.

Other moves:

  • Eli Lilly acquired Calytrix Bio for up to $1.5B, gaining a biparatopic antibody against calreticulin-driven essential thrombocythemia and myelofibrosis — blood cancers with few disease-modifying options.
  • AmyriAD Therapeutics bought AD04 from ADvantage Therapeutics on undisclosed terms. The Phase IIb-ready subcutaneous candidate targets mild Alzheimer's through peripheral inflammation and complements AmyriAD's moderate-stage program.
  • Sanofi signed a multi-target license with Seawolf Therapeutics worth up to $1.2B in milestones plus tiered royalties, centered on the Trident redosable lipid nanoparticle platform for DNA payloads in bleeding disorders.

What is Gilead doing before the data exist?

Gilead signed royalty-free voluntary licenses with Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories covering obeldesivir as potential post-exposure prophylaxis for Ebola Bundibugyo virus disease. The licenses span 127 mostly low- and lower-middle-income countries, including every African nation with reported cases in the current outbreak.

The timing is the unusual part. Obeldesivir is not approved anywhere for filovirus prevention, and trial results are not in. Gilead is building manufacturing and supply capacity now so that, if authorization comes, generics can move immediately rather than spend years negotiating access afterward. "These agreements reflect our commitment to preparing for future access while clinical research is ongoing," said Jaime McCoy, VP of Gilead Patient Solutions. Gilead has also donated more than 38,000 vials of remdesivir for investigational use across the DRC, Uganda and Kenya.

What did the FDA approve?

Two approvals landed, both in steroid- or resistance-constrained settings.

Novartis won approval for Cosentyx (secukinumab) 150 mg in adults with polymyalgia rheumatica who responded inadequately to corticosteroids or cannot tolerate a taper. It is the first anti-IL-17 biologic approved for PMR, a condition treated almost exclusively with long-term steroids — which trigger relapses in up to 40% of patients in year one. In the Phase III Replenish trial, secukinumab doubled the likelihood of sustained remission. "For too long, treatment options beyond glucocorticoids have been limited," said Prof. John Stone, the trial's global principal investigator.

Roche secured approval for Wilserdly (giredestrant) with everolimus in ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after progression on CDK4/6 inhibitors. ESR1 mutations drive resistance in up to 40% of hormone receptor-positive metastatic cases. The Phase III evERA trial showed a 62% reduction in risk of progression or death versus standard endocrine therapy plus everolimus (HR 0.38), in an all-oral regimen. Roche's adjuvant giredestrant application in stages I–III breast cancer sits under Priority Review with a PDUFA date of November 30; approval would be the first new adjuvant endocrine therapy in over 20 years.

Is Lilly building ahead of the science?

Lilly broke ground on a $3.5 billion injectable and device plant in Fogelsville, Pennsylvania, due operational by 2031. The site adds capacity for next-generation obesity treatments, including retatrutide, its investigational once-weekly triple agonist of GIP, GLP-1 and glucagon receptors. It belongs to a $50 billion U.S. manufacturing expansion — 10 sites announced since 2020 — and will create roughly 850 permanent jobs and 2,000 construction jobs. The logic is blunt: capacity, not science, now constrains obesity drug rollout, and Lilly is betting $3.5B on an approval it does not yet hold.

Is Moderna's oncology pivot paying off?

At its November 12 Analyst Day, Moderna raised its 2026 revenue growth outlook to 15–25%, from up to 10% previously, with gross margin expanding about 10 points. Annual cash costs will run $4.0–4.5B from 2027 through 2030, driven by oncology. The centerpiece is intismeran autogene, the individualized neoantigen therapy developed with Merck. The Phase III Interpath-001 trial in resected high-risk melanoma met its primary endpoint: a 42% reduction in risk of recurrence or death and a 38% reduction in distant metastasis or death versus Keytruda alone, published in the New England Journal of Medicine. Commercialization still awaits regulators.

What happened to the FDA's priority voucher program?

The FDA has effectively shelved the Commissioner's National Priority Voucher program, per six sources and internal documents cited by Reuters. Launched in June 2025 under then-Commissioner Marty Makary to cut review times to one or two months, the program drew criticism over potential political influence. Since Makary left in May, no new vouchers have been awarded, the appointee-led executive council has gone dormant, and companies have been informally told the FDA is not advancing applications. Of 22 drugs that received vouchers, 12 are approved — five after Makary's departure, without council review. The nine remaining drugs have returned to career scientists on standard timelines. Penn health policy professor Holly Fernandez Lynch called the outcome "the worst of both worlds." HHS disputes the characterization and says the pilot is ongoing, pending review of June hearing feedback. It has not answered whether a new coordinator was appointed.

via FDA industry wire (Google News) (Source)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

18 articles

Linked filings

  1. T-8005
  2. K-8919
  3. V-6006
  4. K-4995
  5. T-7183

« Previous filingNext filing »